Brind.

Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market.

1 report, 1 independent Updated Sep 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Guardant Health Myriad Genetics Illumina

How it developed

Newest first. Tap a step to see who reported it.

Aug 25BioMark Diagnostics Inc. is developing a high-accuracy liquid biopsy platform specifically for Non-Small Cell Lung Cancer (NSCLC).Sub-event
Sep 2Competition heats up among major players in the liquid biopsy market.1 source
- GlobeNewswire

Keep exploring

The entities involved

Guardant Health
American biotechnology company
- Scott Bessent's call for a rate cut fuels a risk-on environment for companies like agilon health.Sun 05:03
- EVANS welcomed Guardant Health as a sponsor for a coalition planning events across North America.Sat 21:20
Myriad Genetics
American biotechnology company
- MarketBeat is reporting on analyst recommendations and consensus target prices for small-cap healthcare companies Myriad Genetics and Applied DNA Sciences.Fri 11:44
Illumina
American company that develops systems for the analysis of genetic variation

Nothing else this week.

Coverage

Newest first; wire copies grouped

Sep 2GlobeNewswireLiquid Biopsy Market Trends and Industry Forecast to 2030 Featuring Strategic Analysis of Natera, Guardant Health, Myriad Genetics, Illumina, and Roche Among Others Liquid Biopsy Market Dublin, Sept.